Phase 2
Completed N=6
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Source: ClinicalTrials.gov NCT04538950 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcomePrimary: Microvascular Damage/Endothelial Dysfunction — 0 Participants
Summary
Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Microvascular Damage/Endothelial Dysfunction |
— | — |
Eligibility Criteria
Inclusion Criteria
- First time administration of ICI
- Willing and able to return in 4-6 weeks for follow-up study
- Patients with previous heart conditions included (while this may impact MFR the delta MFR is what we are assessing)
Exclusion Criteria
- Age < 18 years
- Women who are pregnant, or breast-feeding.
- Unable or unwilling to give consent to undergo PET/CT.
Data sourced from ClinicalTrials.gov (NCT04538950). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.